[Courtesy of GI Innovation]
[Courtesy of GI Innovation]

GI Innovation's next-generation anticancer drug candidate GI-101A has received fast track designation from the US Food and Drug Administration.

GI Innovation announced Wednesday that the FDA granted fast track designation to GI-101A for the treatment of locally advanced and metastatic urothelial carcinoma in patients who had previously received immunotherapy.

The FDA's fast track program is designed to accelerate the development of innovative new drug candidates that address unmet medical needs in serious or life-threatening conditions. The designation enables closer collaboration between the developer and the FDA to shorten development timelines, and additional benefits such as priority review or accelerated approval can reduce the regulatory review period to six months, bringing commercialization closer.

In a Phase 1 combination therapy trial involving four patients with advanced or metastatic urothelial carcinoma who had failed prior immunotherapy, GI-101A demonstrated an objective response rate of 50 percent and a disease control rate of 75 percent. The data drew notice when presented orally at the American Society of Clinical Oncology annual meeting (ASCO 2026) earlier this year.

Urothelial carcinoma that has progressed after immunotherapy carries a median progression-free survival of only about six months, underscoring strong demand for new treatment options. Patients who achieved partial responses in the GI-101A and Keytruda combination therapy have maintained their responses for more than two years and more than seven months, respectively, with the benefit persisting even after the ASCO presentation.

The fast track designation recognizes GI-101A's clinical efficacy and innovation in a patient population with metastatic urothelial carcinoma that had in effect no viable alternatives after failing first-line immunotherapy. Analysts say the designation significantly raises the prospects for global technology exports and early commercialization.

"The Phase 2 combination trial with Keytruda is progressing smoothly, with enrollment advancing rapidly since the first patient was dosed in May," said Jang Myung-ho, chief executive of GI Innovation. "The FDA completed its designation process in just two weeks — a procedure that typically takes 60 days — and we will use this momentum to accelerate clinical development and bring new treatment opportunities to patients with significant unmet needs."


silverpaper@heraldcorp.com